A Phase 4 interventional study of Desmopressin (DDAVP) and Sodium Chloride in Bleeding, Transplant, Kidney and Desmopressin, sponsored by Hospital de Clinicas de Porto Alegre. Enrolling by invitation at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by Hospital de Clinicas de Porto Alegre · Phase 4, Interventional, and Treatment
The goal of this study is to evaluate the efficacy and safety of desmopressin to prevent bleeding after percutaneous renal graft biopsy in patients at high risk of bleeding.
Researchers will compare desmopressin (DDAVP) to placebo to see if the drug reduces the risk of bleeding events related to kidney biopsy.
Participants will receive intravenous desmopressin medication (100ml) or placebo (100mL of saline solution) before the kidney biopsy.
3,000 studies on the registry are indexed under Hemorrhage; 474 are open to participants now.
This study's planned enrollment of 96 is close to the median of 100 across 1,985 interventional studies indexed under Hemorrhage.
Browse Hemorrhage studies →Hospital de Clinicas de Porto Alegre is the lead sponsor of 450 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Sodium Chloride
Drug: Desmopressin (DDAVP)
Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure
Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure
Bleeding events
Incidence of bleeding related to the procedure
Time frame: Immediately post-biopsy until 48 hours post-biopsy
Major bleeding
Incidence of major bleeding, defined as need for transfusion of blood components, need for embolization, nephrectomy or procedure-related death
Time frame: Immediately post-biopsy until 48 hours post-biopsy
Minor bleeding
Incidence of minor bleeding, defined as presence of macroscopic hematuria, hematoma on ultrasound 24 hours post-procedure or drop in hemoglobin greater than 20%
Time frame: Immediately post-biopsy until 48 hours post-biopsy
Number of participants with hyponatremia, skin reaction, anaphylaxis
Number of participants with hyponatremia, skin reaction, anaphylaxis \[Safety and Tolerability\]
Time frame: Immediately pre-biopsy until 24 hours post-biopsy
Plan to share: Undecided — it is not known whether there will be a plan to make IPD available.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital de Clinicas de Porto Alegre